Clinical trial
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
NCT00458393 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00458393 |
|---|---|
| Title | Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men |
| Official title | Chemoprophylaxis for HIV Prevention in Men |
| Acronym | iPrEx |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Bill and Melinda Gates Foundation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | daily TDF/FTC, Placebo |
| Enrollment | 2,499 |
| Start date | Jun 1, 2007 |
| Primary completion | Feb 1, 2014 |
| Completion | Feb 1, 2014 |
| First posted | Apr 10, 2007 |
| Last update posted | Nov 2, 2021 |
| Countries | Brazil, Ecuador, Peru, South Africa, Thailand, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: